[18F] fluoride cryptate complexes for radiolabeling fluorinations

Abstract

The present invention claims UV detectable (>210 nm) potassium [.sup.18F]fluoride diaryl- and aryl-fused [2.2.2]cryptate complexes suitable for performing radio-labeling reactions to generate [.sup.18F] fluorinated species.

Claims

1. A cryptate compound of the general formula (I), (II), (III), (IV), (V) for radiolabeling fluorinations, wherein cryptate is composed of UV detectable at wavelength 272 nm and molar absorptivity values selected from group of 42222, 40625, 41429, 41667, 41818, 42000, 41250, 42857 M.sup.1cm.sup.1 diaryl- and aryl-fused [2.2.2]cryptand and potassium [.sup.18F]fluoride: ##STR00003## wherein R1, R2, R3, and R4 are each independently selected from H, or a lower alkyl, or lower alkenyl, or alkoxyl, or benzyloxy, or ester, or amide, and or bromine.

2. The cryptate of claim 1 comprises dibenzo[2.2.2]cryptand.

3. The cryptate of claim 1 comprises dinaphtho[2.2.2]cryptand.

4. A method of using a cryptate of claim 1 to radiolabel [.sup.18F]fluorinated species.

5. The method according to claim 4, wherein the radiolabeled [.sup.18F]fluorinated species is viewed by an imaging technique.

6. The method according to claim 5, wherein the imaging technique is a PET scanner.

7. A method of synthesizing Potassium [.sup.18F]fluoride cryptate complexes of the general formula (I), (II), (III), (IV), (V) by combining [.sup.18F]fluoride anion with UV detectable at wavelength 272 nm and molar absorptivity values selected from group of 42222, 40625, 41429, 41667, 41818, 42000, 41250, 42857 M.sup.1cm.sup.1 diaryl and aryl fused [2.2.2]cryptand and potassium carbonate: ##STR00004## wherein R1, R2, R3, and R4 are each independently selected from H, or a lower alkyl, or lower alkenyl, or alkoxyl, or benzyloxy, or ester, or amide, and or bromine.

8. The cryptate complex of claim 7, wherein the diaryl and aryl fused [2.2.2]cryptand comprises dibenzo[2.2.2]cryptand.

9. The cryptate complex of claim 7, wherein the diaryl and aryl fused [2.2.2]cryptand comprises dinaphtho[2.2.2]cryptand.

10. A method comprising cryptate complex according to claim 7 to radiolabel [.sup.18F]fluorinated species.

11. The method according to claim 10, wherein the radiolabeled [.sup.18F]fluorinated species is viewed by an imaging technique.

12. The method according to claim 11, wherein the imaging technique is a PET scanner.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 shows absorbance spectra for acetonitrile reagent.

(2) FIG. 2 shows absorbance spectra for methanol reagent.

(3) FIG. 3 shows absorbance versus wavelength for K-22288, from 0.18 mM-0.068 mM at pH=3

DETAILED DESCRIPTION OF THE INVENTION

(4) The effect of substituents on macrocyclic molecules was first observed by Pedersen (Pedersen, C. J. J. Am. Chem. Soc. 1967, 89, 7017). Subsequently, many different moieties have been introduced into the macrocyclic backbone to modify the properties of the hosts, e.g., to increase rigidity and lipophilicity, (Marchand, A. P.; Huang, Z.; Chen, Z.; Hariprakasha, H. K; Namboothiri, I. N. N.; Brodbelt, J. S.; Reyzer, M. L. J. Heterocyclic Chem. 2001, 38, 1361). The effect of increased rigidity introduced by the incorporated moiety can be interpreted in terms of preorganization. The principle of preorganization (Cram, D. J. in From Design to Discovery American Chemical Society, Washington D.C., 1991, p 9) states: The more highly hosts and guests are organized for binding and low solvation prior to complexation, the more stable will be the complexes. The topology, along with ring size determines the degree of preorganization of a specific structure for complexation. The general trend is that the two-dimensional structure develops into a three dimensional structure, wherein, for similar ring-size, the rigidity of the molecule increases. For example, rigidity increases along the series 18-crown-6, [2.2.2]-cryptand. Increasing rigidity in this way restricts the ability of the ligand to undergo conformational reorganization. Thus more rigid ligands are more highly preorganized. Since the host must undergo conformational adjustment to provide a proper binding environment during the host-guest interaction. Thus, preorganization of a ligand, which is associated with its topology, rigidity and solvation, becomes important. For a specific guest, the more highly preorganized ligand requires less conformational change and thus pays minimal energy cost for conformational adjustment.

(5) Increasing rigidity of the host the more highly preorganized host and the more highly host and guest are organized for binding the more stable the complexes will be.

(6) In order to attain high, yet selective binding of a potassium ion chelator some rigidity in the system such as the ionophore dibenzo-[2.2.2] cryptand was considered necessary.

(7) The cavity size of [2.2.2] cryptand (2.8 A in diameter) closely matches the size of potassium cation (2.66 A).

(8) Substituted [2.2.2] cryptands, such as dibenzo[2.2.2] cryptand (VII) possess a guest binding site (ionophore) having heteroatom With nonbonding electron pairs such as nitrogen, capable of binding potassium (K.sup.+) selectively in its cavity. VII as phase transfer reagent (PTR) in the synthesis of [18F]fluoride cryptate complexes for radiolabeling fluorinations will have improved detectability which will facilitate reliable assessment of PTR in the emerging direction of automated QC testing platforms. VII has strong UV absorbance at >210 nm wavelength. Molar absorptivity values for VII are high across a wide range of pH, 4100 M.sup.1cm.sup.1 at pH 2.4-3.0 (272 nm), and 4400 M.sup.1cm.sup.1 at pH 6.2-6.6 (276 nm). K-222 has its absorbance maximum 200 nm where there is significant issues with solvent interference.

(9) The synthesis of dibenzo-cryptand [2.2.2]; namely 4,7,13,16,20,23-hexaoxa-1,10-diaza-19(1,2),24(1,2)-dibenzabicyclo[8.8.6]tetracosaphane (VII) is outlined in Scheme 1. The commercially available 2-nitrophenol (I) was chosen as a starting material. Treatment of two equivalents of (I) with 1,2-dibromoethane and potassium carbonate in dimethyl formamide (DMF) afforded 1,2-Bis (2-nitrophenoxy)ethane (II). Reduction of (II) with 10% Palladium-on-charcoal as the catalyst produced the amino derivative (III). The diamine (III) was reacted with 3,6-dioxaoctanedioyl dichloride (1,2-ethylene-O,O-diglycolic acid chloride) in tetrahydrofuran (THF) at high dilution conditions in tetrahydrofuran (Dietrich, B.; Lehn, J. M.; Sauvage, J. P.; Blanzat, J. Cryptates. X. Syntheses and physical properties of diazapolyoxamacrobicyclic systems. Tetrahedron 1973, 29, 1629) to give the lactam (IV). The lactam (IV) was reduced with Lithium Aluminum Hydride (LiAH4) in THF to give the azacrown (V) (Previously reported by de Silva, A. P.; Gunaratne, H. Q. N.; Samankumura, K. R. A. S. A new benzo-annelated cryptand and a derivative with alkali cation-sensitive fluorescence. Tetrahedron Lett. 1990, 31, 5193-5196). Subsequent treatment of (V) with 3,6-dioxaoctanedioyl dichloride gave (VI) which upon reduction with diborane in tetrahydrofuran (Pettit, W. A.; Iwai, Y.; Berfknecht, C. F.; Swenson, D. C. Synthesis and structure of N.sup.1-e-benzo-4,7,13,16,21,26-hexaoxa-1,10-diazabicyclo[8.8.8]hexacos-23-yl-N.sup.2-phenylthiourea. Derivative of a bifunctional complexing agent. J. Heterocycl. Chem 1992, 29, 877) furnished the cryptand (VII) (Naguib, Y M A. Molecules 2009, 14, 3600-3609).

(10) ##STR00002##

(11) Di-substituted [2.2.2] cryptand possesses a guest binding site (ionophore) having heteroatom with nonbonding electron pairs such as nitrogen, capable of binding potassium (K.sup.+) selectively in its cavity.

(12) Cryptand is a phase-transfer agent used to complex [.sup.18F] fluoride in non-aqueous environment to form [.sup.18F] fluoride cryptate complexes suitable for performing radio-labeling reactions to generate [.sup.18F] fluorinated species to be viewed through an imaging agent such as Positron Emmision Tomography (PET) and that a [.sup.18F] fluorinated species defined herein comprises chemical or biological [.sup.18F] fluorinated compounds for use as imaging agents. Several approaches for incorporating .sup.18F in biomolecules are described in the following references: Kuhnast, B., et al. (2004) J. Am. Chem. Soc., 15, 617-627; Garg, P. K., et al. (1991) Bioconj. Chem., 2, 44-49; Lee, B. C., et al. (2004) J. Am. Chem. Soc., 15, 104-111; Chen, X., et al. (2004) J. Am. Chem. Soc., 15, 41-49; Glaser, M., et al. (2004) J. Am. Chem. Soc., 15, 1447-1453; Toyokuni et al. Bioconjug. Chem. (2003) 14: 1253-9; and Couturier, O., et al. (2004) Eur. J. of Nuc. Med. and Mol. Imaging 31, 1182-1206).

(13) The present invention is not to be limited in scope by specific to embodiments described herein. Indeed, various modifications of the inventions in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

(14) Various publications and patent applications are cited herein, the disclosures of which are incorporated by reference in their entireties.

REFERENCES

(15) Jewett et al, Multiphase Extraction: Rapid Phase Transfer of [18F] Fluoride Ion for Nucleophilic Radiolabeling Reactions, Appl. Radiat. Isot., vol. 39, No. 11, pp. 1109-1111, 1988

(16) No-Carrier-Added (NCA) ARYL [.sup.18F] Fluorides Via the Nucleophilic Aromatic Substitution of Electron-Rich Aromatic Rings, Ding et al. Journal of Fluorine Chemistry vol. 48, pp. 189-205 (1990)

(17) The Synthesis of 6-[.sup.18F] Fluoro-L-Dopa by Chiral Catalytic Phase-Transfer Alkylation, C. Lemaire et al., J. Label Labelled Cpd., Radiopharm 42 (1999) S113-S115

(18) F-18 labeled biomolecules for PET studies in the neurosciences, Ding YS, Journal of Flourine Chemistry, 101:(2)291-295 Feb. 2000

(19) Proton Irradiation of [180]02: Production of [.sup.18F]F2 and [.sup.18F]F2+[.sup.18F]OF2, Allyson Bishop et al., Nuclear Med. Biol. 1996, 23, 189-199

(20) 4-[.sup.18F]Fluoroarylalkylethers via an improved synthesis of n.c.a. 4-[.sup.18F]fluorophenol,T. Ludwig et al., Nuclear Medicine and Biology 29 (2002) 255-262

(21) Babb, D.A., et al., Synthesis of Hydroxymethyl-Functionalized-Diazacrowns and Cryptands, Journal of Heterocyclic Chemistry 23:609-613 (1986)

(22) Blasius, E., et al., Preparation and Application of Polymers with Cyclic Polyether Anchor Groups, Pure & App. Chem. 54(11):2115-2128 (1982)

(23) Bradshaw, J.S., et al., Stable Silica Gel-Bound Crown Ethers. Selective Separation of Metal Ions and a Potential for Separations of Amine Enantionmers, Journal of Inclusion Phenomena and Molecular Recognition in Chemistry 7:127-136 (1989)

(24) Bradshaw, J.S., et al., Silica gen-bound aza-crowns for the selective removal and concentration of metal ions, Pure & Appl. Chem. 61:1619-1624 (1989)

(25) Krakowiak, K.E., et al., Syntheses of the Cryptands. A Short Review, Israel Journal of Chemistry 32:3-13 (1992)

(26) Krakowiak, K.E., et al., One-step Methods to Prepare Cryptands and Crowns Containing Reactive Functional Groups, Journal of Heterocyclic Chemistry 27:1011-1014 (1990)

(27) Krespan, C.G., Funtionalized Macroheterobicyclic Compounds, Journal of Organic Chemistry 45:1177-1180 (1980)

(28) Montanari, F., et al., Hydrocymethyl Derivatives of 18-Crown-6 and [2.2.2] Cryptand: Versatile Intermediates for the Synthesis of Lipophilic and Polymer-Bonded Macrocyclic Ligands,, J. Org. Chem., 47:1298-1302 (1982)

(29) Dietrich, B., Cryptands, in Comprehensive Supramolecular Chemistry, Atwood et al. eds., Jean-Marie Lehn--Chairman of the Editorial Board, New York: Pergamon, 1996, vol. 1, G.W. Gokel, ed., pp. 154-157, 186, 192